1. Fine-mapping, trans-ancestral and genomic analyses identify causal variants, cells, genes and drug targets for type 1 diabetes
- Author
-
Robertson, Catherine C, Inshaw, Jamie RJ, Onengut-Gumuscu, Suna, Chen, Wei-Min, Santa Cruz, David Flores, Yang, Hanzhi, Cutler, Antony J, Crouch, Daniel JM, Farber, Emily, Bridges, S Louis, Edberg, Jeffrey C, Kimberly, Robert P, Buckner, Jane H, Deloukas, Panos, Divers, Jasmin, Dabelea, Dana, Lawrence, Jean M, Marcovina, Santica, Shah, Amy S, Greenbaum, Carla J, Atkinson, Mark A, Gregersen, Peter K, Oksenberg, Jorge R, Pociot, Flemming, Rewers, Marian J, Steck, Andrea K, Dunger, David B, Wicker, Linda S, Concannon, Patrick, Todd, John A, and Rich, Stephen S
- Subjects
Pediatric ,Biotechnology ,Human Genome ,Diabetes ,Genetics ,Autoimmune Disease ,2.1 Biological and endogenous factors ,Aetiology ,Metabolic and endocrine ,Alleles ,Autoimmunity ,CD4-Positive T-Lymphocytes ,Chromosome Mapping ,Diabetes Mellitus ,Type 1 ,Drug Discovery ,Gene Expression ,Genetic Predisposition to Disease ,Genetic Variation ,Genomics ,Humans ,Molecular Targeted Therapy ,Protein Interaction Mapping ,Type 1 Diabetes Genetics Consortium ,Biological Sciences ,Medical and Health Sciences ,Developmental Biology - Abstract
We report the largest and most diverse genetic study of type 1 diabetes (T1D) to date (61,427 participants), yielding 78 genome-wide-significant (P
- Published
- 2021